Deep vein thrombosis is the abnormal clotting of blood in the deep veins and is a disorder of venous return in the lower extremities. Ace Therapeutics offers customers comprehensive services in basic research and drug development to further explore the pathogenesis and novel therapeutic approaches to deep vein thrombosis.
When a blood clot occurs in a superficial vein, it is called superficial vein thrombosis. However, when a clot occurs in a deep vein, the clot dislodges into the bloodstream and usually reaches the lungs, causing a pulmonary embolism. Almost all blood clots are dislodged and transformed into emboli, and for this reason deep vein thrombosis is sometimes referred to as thromboembolic disease. There are two main causes of deep vein thrombosis, including venous damage and coagulation disorders.
Fig. 1 Interaction of neutrophil extracellular traps with cells and molecules in venous thrombosis. (Yao M, et al., 2023)
In the early stages of deep vein thrombosis, pharmacologic strategies such as anticoagulation and thrombolytic therapy are often used. In recent years, a number of emerging drug types and new targets have also been heavily utilized in the development of drugs for the therapy of deep vein thrombosis.
Overview of Novel Drugs for Deep Vein Thrombosis
| Drug Name | Drug Target | Original Organization | Drug Phase |
|---|---|---|---|
| Apixaban | Coagulation Factor Xa | Bristol Myers Squibb Co. | Approved |
| Edoxaban Tosylate | Coagulation Factor Xa | Daiichi Sankyo Co., Ltd. | Approved |
| Dabigatran Etexilate Mesylate | Thrombin | C.H. Boehringer Sohn AG and Co. KG | Approved |
| NPB-06 | Coagulation factor | Takeda Pharmaceutical Co., Ltd. | Phase 3 |
| Abelacimab | Coagulation Factor XIa | Novartis Pharma AG | Phase 3 |
| BAY-3018250 | A2AP | Bayer AG | Phase 2 |
| SR-059 | Coagulation Factor XI | Suzhou Ribo Life Science Co., Ltd. | Phase 1 |
| SRSD-107 | Coagulation Factor XI | Sirius Therapeutics Co., Ltd. | Phase 1 |
Ace Therapeutics provides outsourced research services for the development of disease models and related research technology platforms to support basic research and the development of novel therapeutic approaches to deep vein thrombosis.
Research Models
Basic Research
Drug Development
We are able to provide the following research models or custom model development services for deep vein thrombosis research.
Custom Animal Model Development Services
We can provide animal models of coronary atherosclerosis and thrombosis to meet our clients' needs for experiments on the pathogenesis and pharmacological evaluation of deep vein thrombosis.
Transgenic Animal Model Development Services
We are able to offer our clients development services of transgenic or knockout animals for deep vein thrombosis research, including but not limited to the following genes:
Genetically Engineered Mouse Models
We can provide the following high quality genetically engineered mice for research into deep vein thrombosis.
Based on our complete pathology and imaging technology platform, we can help our clients discover and identify biomarkers for deep vein thrombosis and evaluate the efficacy of drug therapy in animal models.
Novel Biomarker Discovery Services
With our mature multi-omics research technology platform, we can provide customized deep vein thrombosis biomarker discovery services for our clients.
Pathology and Imaging Services
We can provide technical support for status monitoring in deep vein thrombosis research, and help researchers obtain accurate data from animal experiments.
Based on our professional research team and novel drug research technology platform, we can provide research outsourcing services for deep vein thrombosis, including but not limited to the following drug types and targets:
R&D Services by Drug Type
R&D Services by Target
Ace Therapeutics has accumulated extensive knowledge in the field of cardiovascular disease research and offers a full range of basic research and novel therapy discovery services. If you are interested in our services for deep vein thrombosis, please don't hesitate to contact us.
Ace Therapeutics offers comprehensive solutions and R&D services to researchers worldwide to advance the field of cardiovascular diseases.
We do not provide medical care for patients.
Copyright © Ace Therapeutics. All rights reserved.